Bayesian Capital Management’s Health Catalyst HCAT Stock Holding History

Bayesian Capital Management’s Portfolio HCAT Stock Details HCAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,691	Closed	-$125K	–	908
2023 Q1	$125K	Sell	10,691 -55,500	-84%	-$707K	0.02%	659
2022 Q4	$704K	Buy	+66,191	New	+$639K	0.1%	263

Other funds holding HCAT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Daventry Group New York $133M AUM 32.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Bayesian Capital Management's HCAT Position: Q2 2023 in Review

Bayesian Capital Management sold out of Health Catalyst (HCAT) in Q2 2023, closing a stake of 10,691 shares — an estimated $125K sold.

Bayesian Capital Management first reported a position in HCAT in Q4 2022 and held it in 2 quarters. The position peaked at $704K in Q4 2022. 154 funds tracked by Wall St. Rank hold HCAT as of Q2 2023.

Bayesian Capital Management reported no remaining Health Catalyst position as of Q2 2023 after selling out during the quarter.
Bayesian Capital Management sold 10,691 Health Catalyst shares in Q2 2023, an estimated $125K.
Bayesian Capital Management first reported a position in Health Catalyst in Q4 2022 and held it in 2 quarters.
Bayesian Capital Management's Health Catalyst position peaked at $704K in Q4 2022.
154 funds tracked by Wall St. Rank held Health Catalyst as of Q2 2023.

Based on Bayesian Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.